Juan Martin Arriaga
Overview
Explore the profile of Juan Martin Arriaga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dutta A, Rodriguez-Calero A, Ronaldson-Bouchard K, Offermann A, Rahman D, Vhatkar T, et al.
Mol Cancer Res
. 2025 Feb;
PMID: 39907729
Metastasis accounts for the overwhelming majority of cancer deaths. In prostate cancer and many other solid tumors, progression to metastasis is associated with drastically reduced survival outcomes, yet the mechanisms...
2.
Nunes de Almeida F, Vasciaveo A, Antao A, Zou M, Di Bernardo M, de Brot S, et al.
bioRxiv
. 2024 Sep;
PMID: 39253480
Summary: Using an unbiased forward mutagenesis screen in an autochthonous mouse model, we have investigated mechanistic determinants of aggressive prostate cancer. SIRT1 emerged as a key regulator of neuroendocrine prostate...
3.
Vasciaveo A, Arriaga J, Nunes de Almeida F, Zou M, Douglass E, Picech F, et al.
Cancer Discov
. 2022 Nov;
13(2):386-409.
PMID: 36374194
Significance: OncoLoop is a transcriptomic-based experimental and computational framework that can support rapid-turnaround coclinical studies to identify and validate drugs for individual patients, which can then be readily adapted to...
4.
Arriaga J, Bravo A, Mordoh J, Bianchini M
Oncol Rep
. 2017 Apr;
37(5):2633-2651.
PMID: 28393194
Metallothioneins (MTs) are a family of low-molecular-weight, cysteine-rich proteins involved in zinc and redox metabolism, that are epigenetically downregulated during colorectal cancer (CRC) progression, but may be re-induced with a...
5.
Tapia I, Aris M, Arriaga J, Blanco P, Mazzobre F, Vega J, et al.
Cryobiology
. 2013 Jul;
67(2):163-9.
PMID: 23850827
CSF470 vaccine is a mixture of four lethally irradiated melanoma cell lines, administered with BCG and GM-CSF, which is currently being tested in a Phase II/III Clinical trial in stage...
6.
Roberti M, Arriaga J, Bianchini M, Quinta H, Bravo A, Levy E, et al.
Cancer Biol Ther
. 2012 Jul;
13(11):1123-40.
PMID: 22825326
Triple negative breast cancers (TNBC) lacking hormone receptors and HER-2 amplification are very aggressive tumors. Since relevant differences between primary tumors and metastases could arise during tumor progression as evidenced...
7.
Aris M, Zubieta M, Colombo M, Arriaga J, Bianchini M, Alperovich M, et al.
J Invest Dermatol
. 2011 Oct;
132(2):365-74.
PMID: 21993558
MART-1 and gp100 are prototypical melanoma antigen (Ag), but their clinical use as vaccines or as targets of cytotoxic lymphocytes achieved modest success. Possible explanations could be that as MART-1...
8.
Arriaga J, Levy E, Bravo A, Bayo S, Amat M, Aris M, et al.
Hum Pathol
. 2011 Aug;
43(2):197-208.
PMID: 21820154
Metallothioneins are a family of small, cysteine-rich proteins with many functions. Immunohistochemical evaluation of all metallothionein 1 + 2 isoforms in colorectal tumors has demonstrated an important down-regulation compared with...
9.
Levy E, Sycz G, Arriaga J, Barrio M, von Euw E, Morales S, et al.
Innate Immun
. 2009 Mar;
15(2):91-100.
PMID: 19318419
Cetuximab, an anti-epidermal growth factor receptor monoclonal antibody, has been shown to increase the median survival of colorectal cancer patients. We previously reported that the expression of HLA-E is significantly...